In what way does lurbinectedin affect cancer cell growth?

Lurbinectedin blocks cancer cell growth by binding to the minor groove of DNA and interfering with RNA polymerase II transcription. This disruption stops cells from producing essential proteins and activates DNA repair mechanisms that lead to cell death.

How does lurbinectedin auscultate the DNA damage response?

Lurbinectedin triggers DNA damage signals that activate repair pathways including homologous recombination and non-homologous end joining. These pathways are activated once transcription stops, transcription-coupled nucleotide excision repair turns into single-strand breaks, and single-strand breaks evolve into double-strand breaks.

How long does lurbinectedin trigger DNA damage after administration?

Damage signals persist for several hours after a dose. Repair pathway activation continues through the time of next administration in typical clinical schedules, often 21 days apart.

Can lurbinectedin reach the transcriptional machinery directly?

Lurbinectedin binds directly to DNA and traps RNA polymerase II, traps it in a position that prevents its release and movement along the genes it needs to transcribe.

What happens if lurbinectedin fails to target DNA?

If lurbinectedin does not bind to DNA, the drugs' ability to stop transcription and activate damage repair pathways becomes limited. That is why it is targeted toward cancer cells with high transcriptional activity.

Why are companies challenging this patent?

Companies challenge patents on lurbinectedin because the drug is approved for relapsed small cell lung cancer and has potential applications in other cancer types.